How can we improve the management of individuals with attention deficit hyperactivity disorders and co-occurring cardiometabolic disease?

Click to increase image sizeClick to decrease image size

Declaration of interest

H Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Shire Pharmaceuticals and Evolan Pharma AB outside the submitted work; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire Pharmaceuticals outside the submitted work.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no [965381], and from Vetenskapsrådet [no. 2022-01119].